

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 03rd of January 2021

Situation Report No. 210 - Kingdom of Saudi Arabia
04th of January, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	83,322,449	1,831,412	4,977,852	122,061
New	740,221	12,502	20,508	397

Kingdom of Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	363,061	354,443	6,246	2,372	358	11,103,188
New	82	180	7	-	-	29,252

HIGHLIGHTS

- Regions with the highest new infections: Riyadh (35), Makkah (24), Eastern (7), Madinah (5), AlQassim (3), Nothren Borders (2), Asir (2), and Tabuk (1).
- Ministry of Health has warned people against responding to fake messages circulated through mobile phones asking them to update their ID via Sehhaty App.
- Non-Saudis arriving from UK and South Africa must stay at least 14 days in another country before entering Saudi Arabia with a PCR test after the expiration of this period.
- Saudi CDC launched the interim guidelines for the use of SARS-CoV-2 vaccine, see link.
- WHO Published guidance on COVID-19 Global Risk Communication and Community Engagement Strategy, see link.
- WHO produces a prepared draft by the SAGE on Immunization Working Group on COVID-19 vaccines.

IMPORTANT LINKS

- MoH COVID-19 updates: <https://twitter.com/saudimoh>
- WHO's COVID-19 global situation reports: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- WHO's COVID-19 dashboard: <https://covid19.who.int/>
- MoH COVID-19 dashboard: <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- CDC's Interim guidelines for the use of SARS-CoV-2 vaccine: <https://covid19.cdc.gov.sa/professionals-health-workers/interim-guidelines-for-the-use-of-sarscov-2-vaccine/>
- WHO guidance on COVID-19 Global Risk Communication and Community Engagement Strategy: <https://www.who.int/publications/i/item/covid-19-global-risk-communication-and-communityengagement-strategy>
- Draft on Immunization Working Group on COVID-19 vaccines: <https://www.who.int/publications/i/item/mrna-vaccines-against-covid-19-pfizer-biontech-covid19-vaccinebnt162b2>

IMPORTANT DEFINITIONS

WHO issues its first emergency use validation for a COVID-19 vaccine

The World Health Organization listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO. This opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine. Regulatory experts convened by WHO from around the world and WHO's own teams reviewed the data on the vaccine's safety, efficacy and quality as part of a risk-versus-benefit analysis. Experts from individual national authorities are invited to participate in the review. The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks. The vaccine is also under policy review to formulate vaccine specific policies and recommendations for this product's use in populations.

IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa

